Lower blood levels of adiponectin, a signaling molecule produced by fat tissue, and the anti-inflammatory molecule interleukin (IL)-10 are associated with faster disease progression and shorter survival in people with amyotrophic lateral sclerosis (ALS), a study in China found. The findings also showed that established prognostic measures, such as…
News
Projenx‘s prosetin was found to be safe and well tolerated at doses that engaged its therapeutic target in people with amyotrophic lateral sclerosis (ALS), supporting its continued development as a potential disease-modifying therapy. These interim data from the fully enrolled PRO-101 Phase 1 clinical trial (NCT05279755), including…
When a parent develops amyotrophic lateral sclerosis (ALS), adult children may face heavy emotional pressures and may have difficulty balancing family, work, and personal life, highlighting the need for emotional support and guidance from both healthcare professionals and others who have gone through similar experiences. “Due to the profound…
Cases of motor neuron diseases — including amyotrophic lateral sclerosis (ALS), the most common of these — are increasing in European countries. A study suggests the reason is not solely because of an aging population, though more people are living longer and neurodegenerative diseases are more common in older…
Masitinib treatment was linked to a nearly doubled five-year survival rate among people with amyotrophic lateral sclerosis (ALS), with higher survival rates seen among patients with slower disease progression and those who started treatment before experiencing a complete loss of functionality. That’s according to new analyses from the…
Neurosense Therapeutics said it recently held a “constructive” meeting with Health Canada to discuss potential regulatory pathways for PrimeC, its experimental oral therapy for amyotrophic lateral sclerosis (ALS). The meeting focused on the company’s proposed new drug submission (NDS) strategy and the clinical, biomarker, and long-term outcomes data…
Researchers using a fish model of amyotrophic lateral sclerosis (ALS) found that damage to the cerebellum — a brain region not traditionally associated with ALS — begins before motor symptoms emerge. This damage appears to be driven by reduced levels of PAICS, an enzyme involved in the production of…
A team at Stanford University has received a $13 million grant to uncover previously unknown genetic causes of amyotrophic lateral sclerosis (ALS), with the goal of identifying targets for future treatments. The grant, awarded by the California Institute for Regenerative Medicine (CIRM) to a team led by Stanford…
The statistical methods scientists use to analyze outcomes from clinical trials in amyotrophic lateral sclerosis (ALS) vary widely, and these differences may make some trials prone to generating misleading results, a study found. The researchers focused on analysis of the ALS Functional…
Two leaders at Brainstorm Cell Therapeutics, which is developing the experimental cell-based therapy NurOwn (debamestrocel) for people with amyotrophic lateral sclerosis (ALS), have published a paper calling on the U.S. Food and Drug Administration (FDA) to modernize its review process for experimental therapies for ALS and other…
Recent Posts
- Lower levels of two molecules linked to faster ALS progression, shorter survival
- This ALS caregiver is learning to hit the pause button
- Oral prosetin proves safe in early trial, paving way for Phase 2
- Adult children of parents with ALS may need more support, study finds
- A funny thing happened on the way to the ALS forums